1. The role of methylation profiling in histologically diagnosed neurocytoma: a case series
- Author
-
Kalawi, Adam Z, Malicki, Denise M, Abdullaev, Zied, Pratt, Drew W, Quezado, Martha, Aldape, Kenneth, Elster, Jennifer D, Paul, Megan R, Khanna, Paritosh C, Levy, Michael L, and Crawford, John R
- Subjects
Male ,Cancer Research ,Pediatric brain tumor ,Oncology and Carcinogenesis ,Synaptophysin ,Methylation ,Rare Diseases ,Clinical Research ,Pediatric neurocytoma ,Humans ,Neurocytoma ,Oncology & Carcinogenesis ,Child ,Cancer ,Pediatric ,screening and diagnosis ,Brain Neoplasms ,Neurosciences ,Magnetic Resonance Imaging ,Brain Disorders ,Brain Cancer ,Detection ,Ki-67 Antigen ,Neurology ,Oncology ,Atypical neurocytoma ,Female ,Patient Safety ,Neurology (clinical) ,4.2 Evaluation of markers and technologies - Abstract
Purpose To highlight the clinical, neuroradiographic, neuropathologic, and molecular features of histologically identified neurocytoma in a pediatric cohort and highlight the evolving use methylation profiling in providing diagnostic clarity in difficult to diagnosis pediatric brain tumors. Methods Five consecutive children (ages 9–13, 2 girls 3 boys) were histologically diagnosed with neurocytoma at Rady Children’s Hospital San Diego from 2012 to 2018. Clinical and molecular features were analyzed with regards to treatment course and outcome. Results Presenting symptoms included seizures (n = 2), syncope (n = 1), headache (n = 2), visual disturbances (n = 2) and emesis (n = 2). Tumor location included intraventricular (n = 2), intraventricular with parenchymal spread (n = 1), and extraventricular (n = 2). Magnetic resonance imaging demonstrated reduced diffusivity (2/5), signal abnormality on susceptibility-weighted sequences (3/5), and varying degrees of contrast enhancement (4/5). All patients underwent surgical resection alone. Recurrence occurred in four children that were treated with surgery (4/4), adjuvant radiation (2/4), and chemoradiation (1/4). Neuropathologic features included positivity for GFAP (4/5), synaptophysin (4/5), NSE (2/2), NeuN (4/4), and variable Ki-67 ( Conclusion Neurocytomas are a rare clinical entity that warrants further investigation into molecular and pathologic prognosticating features. Methylation profiling may aid in differentiation of neurocytoma from other difficult to diagnose tumors who share similar histologic features.
- Published
- 2022